Contact Us
Hit enter to search or ESC to close

News

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics
– Preliminary Data from ATH434-202 Study Expected in 1H 2024 – – ATH434-201 Study to Complete in November 2024 – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders. Dear Shareholders: As we begin a new ...

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
Alterity Therapeutics
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 16 November 2023:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 was presented at the Society for Neuroscience that took place November 11-15, 2023, in Washington, ...

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
Alterity Therapeutics
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 15 August 2023. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$4.74 million cash refund from the Australian Taxation Office under the Australian Government’s Research and ...

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
Alterity Therapeutics
Highlights: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 July 2023. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2023 (Q4 ...

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
Alterity Therapeutics
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present a corporate overview and participate in a Q&A discussion at the MST Access Rare Diseases, Rich Returns Forum on Thursday, ...

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
Alterity Therapeutics
– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 27 March 2025:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last ...

Alterity Therapeutics Raises A$40.0 million in Placement
Alterity Therapeutics
– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 10 February 2025:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a biotechnology company dedicated to developing disease ...

Alterity Therapeutics Announces Funding to Accelerate ATH434 Clinical and Business Development Activities
Alterity Therapeutics
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 3 February 2025:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it raised capital in the U.S. to accelerate clinical development and business development activities for the Company’s lead asset, ATH434. Based ...

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Alterity Therapeutics
– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – –  Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions – –  ATH434 Demonstrated a Favorable Safety Profile – – Webcast Today at 11:00 a.m. ...

Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 17 January 2025:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, has released a Shareholder Newsletter. You can access the full newsletter in this link: https://mailchi.mp/we-worldwide/alterity-therapeutics-shareholder-newsletter-january-2025 Below is an excerpt of the newsletter, a ...

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Alterity Therapeutics
– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 December 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative ...

Chairman’s Address 2024 Annual General Meeting
Alterity Therapeutics
Good morning, everyone, and thank you for joining us today here in Melbourne.  It is my pleasure to share with you my Chairman’s address for Alterity Therapeutics Fiscal Year 2024 Annual General Meeting. This has been a year of significant progress and achievement for Alterity, marked by important milestones in our mission to develop disease-modifying ...

Receive news from Alterity Therapeutics

Subscription Form